Epha2-binding pending peptide and composition comprising same
AssigneePeptiDream Inc.
InventorsTakanori Aoki, Takeru Ehara, Sora Enya, Makoto Jitsuoka, Kouki Morimoto, Shunichi Nakano, Takayuki Nagasawa, Masaki Ohuchi, Hayato Yanagida, Zaid Amso, Rongjun He, Derek Cole
Life of this patent
Estimating the term…
Abstract
The present technology generally relates to peptides that bind to the Eph receptor A2 (EphA2), to peptides that bind to the EphA2, and to compositions comprising such peptides.
Claims114
A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide comprises an amino acid sequence including deletion, substitution, and/or addition of one or several (e.g., 1-6) amino acids in the amino acid sequence of SEQ ID NO:
- 1:
- (SEQ ID NO:
- 1)
- da-MeF-N-L-Hgl-MeF-W1Me-V-W1Me-T-E-C
- or a pharmaceutically acceptable salt thereof, wherein the (cyclic) peptide consists of 10 to 12 amino acid residues.
A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide comprises an amino acid sequence of Formula (I), or a pharmaceutically acceptable salt thereof,
- wherein,
- X1 is an amino acid;
- X2 is an amino acid comprising an aromatic ring, an N-methylated amino acid thereof, or a variant thereof;
- X3 is a hydrophilic amino acid (e.g. N, Q, Cit, K or a variant thereof), glycine (G), Alanine (A) or a variant thereof (e.g., da, 2-Aminoisobutyric acid (Aib);
- X4 is a hydrophobic amino acid (e.g., leucine (L)), a hydrophilic amino acid (e.g., citrulline (Cit), or a variant thereof;
- X5 is a hydrophilic amino acid, or a variant thereof;
- X6 is a hydrophilic amino acid, an amino acid comprising an aromatic ring, or an N-methylated amino acid thereof;
- X7 is an amino acid comprising an aromatic ring (e.g., W, F, or a variant thereof);
- X8 is a hydrophobic amino acid, a hydrophilic amino acid, an N-methylated amino acid, or a variant thereof;
- X9 is an amino acid comprising an aromatic ring (e.g., W or a variant thereof);
- X10 is absent or a hydrophilic amino acid (e.g., Threonine (T) or a variant thereof);
- X11 is absent or a hydrophilic amino acid;
- and
- X12 is cysteine (C) or a variant thereof.
A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide consists of a sequence of Formula (I),
- or a pharmaceutically acceptable salt thereof,
- wherein
- each of X1, X2, X3, X4, X5, X6, and X8 is independently an amino acid;
- X7 is W1Me or a variant thereof;
- X9 is W1Me or a variant thereof;
- each of X10 and X11 is independently absent or an amino acid;
- and
- X12 is cysteine (C) or a variant thereof;
- and,
- optionally, a linker that connects the peptide with a payload molecule.
A (cyclic) peptide having avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide has an amino acid sequence of Formula (I),
- wherein,
- X1 is any D- or L-amino acid;
- X2 has a structure of
- wherein
- ring A2 is phenyl or a 6-membered heteroaryl (e.g., heteroaryl having 1 or 2 N);
- RX2 is each independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)2Ra, —S(═O)2Ra, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl;
- wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl is optionally and independently substituted with one or more RXA;
- kx2 is 0, 1, 2, or 3;
- mx2 is 0, 1, 2, 3 or 4;
- RNX2 is H, C1-C6 alkyl, or C1-C6 haloalkyl;
- *X1 indicates the point of attachment to X1;
- and,
- *X3 indicates the point of attachment to X3;
- X3 has a structure of
- wherein
- kx3 is 0, 1, 2, or 3;
- RNX3 is H, C1-C6alkyl, or C1-C6haloalkyl;
- RX3 is H, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl;
- *X2 indicates the point of attachment to X2;
- and,
- *X4 indicates the point of attachment to X4;
- X4 is a hydrophobic amino acid (e.g., amino acid having 4 or more carbon atoms in a side chain comprising a linear, branched, or cyclic carbon chain), and wherein X4 is optionally N-alkylated by a C1-3 alkyl group;
- X5 is a hydrophilic L-amino acid, such as an amino acid having a structure of
- wherein:
- RNX5 is H, —CN, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl;
- wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, or heteroalkyl is optionally and independently substituted with one or more RXA;
- RXN5 is —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═NR)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl;
- wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, or heteroalkyl is optionally and independently substituted with one or more RXA;
- provided that at least one of RNX5 and RX5 comprises a moiety selected from —OH, —NH2, and —NH— (e.g. —NH—C(═NH)—NH2, —CO—NH2, —NH2, —COOH, —C(OH)—C0-6 alkyl, —NH—CO—C1-6 alkyl);
- *X4 indicates the point of attachment to X4;
- and,
- *X6 indicates the point of attachment to X6;
- X6 is
- wherein
- RNX6 is H, C1-C6alkyl, or C1-C6haloalkyl;
- RX6 is —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═NRb)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;
- wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally and independently substituted with one or more RXA;
- *X5 indicates the point of attachment to X5;
- and,
- *X7 indicates the point of attachment to X7;
- X7 has a structure of
- wherein
- RNX7 is H, C1-C6alkyl, or C1-C6haloalkyl;
- ring A7 is an aryl or heteroaryl;
- RX7 is each independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5;
- —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2-halogen, —S(═O)2NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl;
- wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl is optionally and independently substituted with one or more RXA;
- kx7 is 0, 1, 2, or 3;
- mx7 is 0, 1, 2, 3, 4 or 5;
- *X6 indicates the point of attachment to X6;
- and,
- *X8 indicates the point of attachment to X8;
- X8 is an L-amino acid with —H on the alpha-amino group;
- X9 has a structure of
- wherein
- RNX9 is H, C1-C6alkyl, or C1-C6haloalkyl;
- ring A9 is an aryl or heteroaryl;
- RX9 is each independently halogen, —CN, —NO2, —OH, —ORa, —OC(═O)Ra, —OC(═O)ORb, —OC(═O)NRcRd, —SH, SF5, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)NRcRd, —NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, —NRbS(═O)2Ra, —C(═O)Ra, —C(═O)ORb, —C(═O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, or heterocycloalkyl;
- wherein the alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, or heterocycloalkyl is optionally and independently substituted with one or more RXA;
- kx9 is 0, 1, 2, or 3;
- mx9 is 0, 1, 2, 3, 4, or 5;
- *X8 indicates the point of attachment to X8;
- and,
- *XC indicates the point of attachment to (i) X10 or (i) when X10 and X11 are absent, X12;
- X10 is absent or an L-amino acid;
- X11 is absent or an L-amino acid;
- provided that when X10 is absent, then X11 is also absent;
- and
- X12 is an L-amino acid having a reactive thiol group, such as Cys and Cys variants;
- each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkyl(cycloalkyl), C1-C6alkyl(heterocycloalkyl), C1-C6alkyl(aryl), or C1-C6alkyl(heteroaryl);
- wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
- each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkyl(cycloalkyl), C1-C6alkyl(heterocycloalkyl), C1-C6alkyl(aryl), or C1-C6alkyl(heteroaryl);
- wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
- each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkyl(cycloalkyl), C1-C6alkyl(heterocycloalkyl), C1-C6alkyl(aryl), or C1-C6alkyl(heteroaryl);
- wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
- or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R;
- and
- each R and RXA is independently halogen, —CN, —OH, —OC1-C6alkyl, SF5, —S(═O)C1-C6alkyl, —S(═O)2C1-C6alkyl, —S(═O)2NH2, —S(═O)2-halogen, —S(═O)2NHC1-C6alkyl, —S(═O)2N(C1-C6alkyl)2, —NH2, —NHC1-C6alkyl, —N(C1-C6alkyl)2, —NRbC(═NRb)NRcRd, —NHC(═O)OC1-C6alkyl, —C(═O)C1-C6alkyl, —C(═O)OH, —C(═O)OC1-C6alkyl, —C(═O)NH2, —C(═O)N(C1-C6alkyl) 2, —C(═O)NHC1-C6alkyl, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, or C1-C6heteroalkyl;
- optionally, the peptide is linked to a payload molecule via a linker.
A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), and competes for binding to a human EphA2 with a peptide that has an amino acid sequence including deletion, substitution, or addition of one or several amino acids in the amino acid of SEQ ID NO:
- 1:
- da-MeF—N-L-Hgl-MeF-W1Me-V-W1Me-T-E-C (SEQ ID NO:
- 1)
- or a pharmaceutically acceptable salt thereof.
A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide competes for binding to a human EphA2 with a peptide that has a structure of Formula (I), or a pharmaceutically acceptable salt thereof,
- wherein,
- X1 is an amino acid;
- X2 is an amino acid comprising an aromatic ring, an N-methylated amino acid thereof, or a variant thereof;
- X3 is a hydrophilic amino acid (e.g. N, Q, Cit, K or a variant thereof), glycine (G), Alanine (A) or a variant thereof (e.g., da, 2-Aminoisobutyric acid (Aib);
- X4 is a hydrophobic amino acid (e.g., leucine (L)), a hydrophilic amino acid (e.g., citrulline (Cit), or a variant thereof;
- X5 is a hydrophilic amino acid, or a variant thereof;
- X6 is a hydrophilic amino acid, an amino acid comprising an aromatic ring, or an N-methylated amino acid thereof;
- X7 is an amino acid comprising an aromatic ring (e.g., W, F, or a variant thereof);
- X8 is a hydrophobic amino acid, a hydrophilic amino acid, an N-methylated amino acid, or a variant thereof;
- X9 is an amino acid comprising an aromatic ring (e.g., W or a variant thereof);
- X10 is absent or a hydrophilic amino acid (e.g., Threonine (T) or a variant thereof);
- X11 is absent or a hydrophilic amino acid;
- and
- X12 is cysteine (C) or a variant thereof.
A (cyclic) peptide that has avidity for ephrin type-A receptor 2 (EphA2), wherein the peptide consists of a sequence of Formula (I),
- or a pharmaceutically acceptable salt thereof,
- wherein
- each of X1, X2, X3, X4, X5, X6, and X8 is independently an amino acid;
- X7 is W1Me or a variant thereof;
- X9 is W1Me or a variant thereof;
- each of X10 and X11 is independently absent or an amino acid;
- and
- X12 is cysteine (C) or a variant thereof;
- and,
- wherein the peptide is optionally linked to a payload molecule through a linker.
A conjugate comprising the peptide or salt thereof according to any one of the preceding claims and a substance, wherein the substance is selected from the group consisting of:
- a nucleotide, a small molecule, a medium sized molecule (e.g., with a M.W. of about 1,000-2,500 Da), a large sized molecule (e.g., with a M.W. of >2,500 Da), a polymer compound, a protein, a peptide, a tag, a biological fragment, a carrier including pharmaceutical compound, or a combination thereof.
Use of the peptide or salt thereof according to any one of the preceding claims in the manufacture of a medicament for diagnosing and/or treating a disease or disorder characterized by an overexpression or a decreased expression of EphA2.
The peptide or salt thereof according to any one of the preceding claims, for use in diagnosing and/or treating a disease or disorder characterized by an overexpression or a decreased expression of EphA2.
Dependencies are inferred from the claim text.